Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Slichenmyer

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Seminars in Oncology|November 14, 2001
Anticancer therapy targeting the erbB family of receptor tyrosine kinasesW J Slichenmyer, D W Fry
Cancer Treatment and Research|January 1, 1995
Recent clinical advances with camptothecin analoguesW J Slichenmyer, R C Donehower
Anti-Cancer Drugs|December 1, 1991
Taxol: a new and effective anti-cancer drugW J Slichenmyer, D D Von Hoff
Journal of Clinical Pharmacology|September 1, 1990
New natural products in cancer chemotherapyW J Slichenmyer, D D Von Hoff
Seminars in Oncology|November 14, 2001
CI-1033, a pan-erbB tyrosine kinase inhibitorW J Slichenmyer, W L Elliott, D W Fry
Urology|October 1, 1988
Chronic vasculitis causing unilateral ureteral stenosisG R Goodman, J R Woodside, W J Slichenmyer
Fertility and Sterility|October 1, 1986
The effect of cauterization of the rabbit ovary on adhesion formationS G Awadalla, J H Mattox, W J Slichenmyer
Investigational New Drugs|April 1, 1992
Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose melphalan with autologous bone marrow transplantationW J Slichenmyer, C F LeMaistre, D D Von Hoff
Journal of the National Cancer Institute|February 17, 1993
The current status of camptothecin analogues as antitumor agentsW J Slichenmyer, E K Rowinsky, R C Donehower, et al.
Cancer Research|September 15, 1993
Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damageW J Slichenmyer, W G Nelson, R J Slebos, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|November 14, 2001
Anticancer therapy targeting the erbB family of receptor tyrosine kinasesW J Slichenmyer, D W Fry
Cancer Treatment and Research|January 1, 1995
Recent clinical advances with camptothecin analoguesW J Slichenmyer, R C Donehower
Anti-Cancer Drugs|December 1, 1991
Taxol: a new and effective anti-cancer drugW J Slichenmyer, D D Von Hoff
Journal of Clinical Pharmacology|September 1, 1990
New natural products in cancer chemotherapyW J Slichenmyer, D D Von Hoff
Seminars in Oncology|November 14, 2001
CI-1033, a pan-erbB tyrosine kinase inhibitorW J Slichenmyer, W L Elliott, D W Fry
Urology|October 1, 1988
Chronic vasculitis causing unilateral ureteral stenosisG R Goodman, J R Woodside, W J Slichenmyer
Fertility and Sterility|October 1, 1986
The effect of cauterization of the rabbit ovary on adhesion formationS G Awadalla, J H Mattox, W J Slichenmyer
Investigational New Drugs|April 1, 1992
Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose melphalan with autologous bone marrow transplantationW J Slichenmyer, C F LeMaistre, D D Von Hoff
Journal of the National Cancer Institute|February 17, 1993
The current status of camptothecin analogues as antitumor agentsW J Slichenmyer, E K Rowinsky, R C Donehower, et al.
Cancer Research|September 15, 1993
Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damageW J Slichenmyer, W G Nelson, R J Slebos, et al.
Pageof 2